Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The role of vaccines in AML

David Avigan • 26 Aug 2022
IMS 2022
Acute Myeloid Leukemia Leukemia CAR-T Vaccines

David Avigan, MD, Harvard Medical School, Boston, MA, comments on the challenge of finding a target for CAR-T therapy in acute myeloid leukemia (AML), highlighting the potential role of vaccines in this disease. Dr Avigan explains that it appears that vaccines may have a role in preventing relapse rather than attempting to bring patients into remission. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from David Avigan

2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
1:10
Immune dysregulation in myeloma and impact on disease progression
David Avigan • 26 Aug 2022
3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020
16:02
CAR-T: hurdles and ladders
Adam Cohen et al. • 13 Sep 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals